Selank and Semax in Enzyme Interaction Research
Enkephalin-Degrading Enzymes
A study by Kost and colleagues examined synthetic Semax and Selank in relation to enkephalin-degrading enzymes present in human serum. The researchers used the heptapeptides Semax, Met-Glu-His-Phe-Pro-Gly-Pro, and Selank, Thr-Lys-Pro-Arg-Pro-Gly-Pro. Enkephalin hydrolysis was used as the measured enzyme reaction.
The researchers reported a concentration-dependent inhibitory effect for both peptides. The experiment therefore measured changes in enzymatic hydrolysis within a human serum preparation rather than examining a behavioral or clinical endpoint.
Comparative Enzyme Inhibition
The reported IC50 was 10 µM for Semax and 20 µM for Selank. The researchers also compared the peptides with established peptidase inhibitors, including puromycin and bacitracin. Puromycin had a reported IC50 of 10 mM in the same study.
These measurements describe the relative inhibitory responses observed under the conditions of that particular human-serum experiment. They do not establish equivalent activity in other enzyme preparations or biological models.
Peptide Fragments in Enzyme Inhibition Studies
Selank and Semax Fragments
The same investigation examined shorter fragments derived from the two parent heptapeptides. Pentapeptide fragments also produced an inhibitory effect in the assay. Tripeptide, tetrapeptide, and hexapeptide fragments did not display the same reported activity.
The experiment therefore included both intact heptapeptides and selected shorter peptide forms. The fragment observations apply to the sequences and concentrations tested by the researchers and do not establish activity for every possible derivative.
Parent Peptides Versus Fragments
The researchers compared the intact seven-residue compounds with shorter peptide derivatives within the same experimental system. The pentapeptide derivatives retained measurable inhibitory activity whereas the other tested fragment lengths did not show the same response.
This design treated peptide length as an experimental variable. The results show that the measured enzyme response differed among the specific peptide forms examined in the study. They do not establish a general enzyme response based solely on peptide length.
Peptide–Enzyme Recognition
Sequence Features and Enzyme Interaction
Semax and Selank have different N-terminal sequences while both contain a C-terminal Pro-Gly-Pro sequence. The published inhibition study examined the parent peptides and shorter derivatives allowing researchers to compare enzyme responses associated with different peptide structures.
Separate research examined Semax analogues in which the N-terminal methionine was replaced by alanine, glycine, threonine, or tryptophan. The researchers then examined how these substitutions affected proteolysis by N-aminopeptidases.
Experimental Evidence for Molecular Recognition
The N-terminal substitution study was designed to examine whether changing one defined residue altered enzymatic processing of Semax. The researchers found that the substitutions changed the measured degradation behavior demonstrating that sequence modification can affect proteolysis under the tested conditions.
These experiments do not establish a complete structural model of peptide-enzyme recognition. They do not identify every molecular contact between the peptide and enzyme. The evidence is limited to the biochemical responses measured in the experimental systems used by the researchers.
Experimental Methods Used to Measure Peptide–Enzyme Interactions
Enzyme Activity Assays
A separate human-plasma investigation developed an assay using Leu-enkephalin labeled with tritium throughout its amino-acid residues. Plasma degradation produced radioactive metabolites, which were separated by high-performance liquid chromatography. Unlabeled Leu-enkephalin fragments were used as internal standards during the analysis.
The method allowed the researchers to estimate the contribution of several peptidase classes to total enkephalin-degrading activity. The study examined aminopeptidases, dipeptidylaminopeptidases, dipeptidylcarboxypeptidases, and a carboxypeptidase pathway.
Peptide and Fragment Analysis
Semax degradation studies used high-performance liquid chromatography to follow peptide breakdown and identify resulting products. An early investigation examined Semax degradation in rat blood and serum by HPLC.
Another study used uniformly tritium-labeled peptides with HPLC analysis to examine Semax and Selank degradation. The researchers used isotope labeling to determine peptide concentrations and measure enzyme activity in small biological samples.
A later study applied isotopically labeled Semax together with HPLC and UV detection to analyze peptide fragments formed during incubation with rat brain plasma membranes.
Selank and Semax Beyond the Primary Enzyme Model
Additional Selank Enzyme Research
A 2004 study examined Selank in human plasma using uniformly tritium-labeled Leu-enkephalin. The researchers estimated that aminopeptidases accounted for approximately 80% of the total measured activity, while dipeptidylaminopeptidases accounted for approximately 2% and dipeptidylcarboxypeptidases approximately 10%. A separate carboxypeptidase pathway contributed approximately 6%.
The investigators also reported that Selank showed greater specificity for carboxypeptidases and dicarboxypeptidases within this experimental system. This study therefore provided information about the enzyme classes associated with the measured plasma activity.
Additional Semax Enzyme Research
Semax has been examined in rat blood and serum using selective peptidase inhibitors. Bestatin inhibited up to 66% of the total degrading activity, puromycin inhibited approximately 33%, and lisinopril approximately 15%. The researchers concluded that aminopeptidases and angiotensin-converting enzyme accounted for the major part of Semax hydrolysis in rat serum.
Another investigation examined Semax degradation in rat brain plasma membranes. The researchers considered dipeptidylaminopeptidases to be the main enzymes responsible for the observed biodegradation. Sequential cleavage produced the HFPGP pentapeptide and then the PGP tripeptide.
A separate study examined Semax degradation in rat basal-forebrain cell cultures and plasma membranes. The researchers reported that removal of ME and GP and formation of pentapeptides were predominant processes in the tested preparations. Product patterns differed between glial and neuronal cell preparations.
Experimental Boundaries of Peptide–Enzyme Research
The cited experiments measure defined biochemical endpoints, Inhibition studies measure changes in enzyme activity. Fragment experiments compare selected peptide structures. Proteolysis studies examine peptide cleavage and the products generated under specific experimental conditions.
The biological preparations also differ between studies. Published experiments have used human serum, human plasma, rat blood, rat serum, rat brain membranes, and rat basal-forebrain cell cultures. Results from one preparation therefore cannot automatically be transferred to another experimental system.
An enzyme assay provides a biochemical measurement under defined laboratory conditions. It does not independently establish a human outcome.
The Research Context for Selank and Semax
Published research has examined Selank and Semax through enzyme inhibition, peptide-fragment analysis, peptidase characterization, and proteolytic degradation. The experimental findings are specific to the peptide structures, enzyme preparations, biological materials and analytical methods used in each study.
Research collection: Explore the Direct SARMs peptide research collection.
FAQs
References
- Kost NV, Sokolov OIu, Gabaeva MV, Grivennikov IA, Andreeva LA, Miasoedov NF, Zozulia AA. Ingibiruiushchee deĭstvie semaksa i selanka na énkefalindegradiruiushchie fermenty syvorotki krovi cheloveka [Semax and selank inhibit the enkephalin-degrading enzymes from human serum]]. Bioorg Khim. 2001 May-Jun;27(3):180-3. Russian. https://pubmed.ncbi.nlm.nih.gov/11443939/
- Zolotarev IuA, Sokolov OIu, Kost NV, Vas'kovskiĭ BV, Miasoedov NF, Zozulia AA. Odnorodno mechennyĭ tritiem [Leu]énkefalin v issledovanii ingibiruiushchego deĭstviia Selanka na énkefalindegradiruiushchie fermenty plazmy krovi [Leu-enkephalin homogeneously labeled with tritium in studying the Selank inhibiting effect on the enkephalin-degrading enzymes of human plasma]. Bioorg Khim. 2004 May-Jun;30(3):234-40. Russian. https://pubmed.ncbi.nlm.nih.gov/15344652/
- Potaman VN, Alfeeva LY, Kamensky AA, Levitzkaya NG, Nezavibatko VN. N-terminal degradation of ACTH(4-10) and its synthetic analog semax by the rat blood enzymes. Biochem Biophys Res Commun. 1991 Apr 30;176(2):741-6. https://pubmed.ncbi.nlm.nih.gov/1851003/
- Potaman VN, Alfeeva LY, Kamensky AA, Nezavibatko VN. Degradation of ACTH/MSH(4-10) and its synthetic analog semax by rat serum enzymes: an inhibitor study. Peptides. 1993 May-Jun;14(3):491-5. https://pubmed.ncbi.nlm.nih.gov/8392718/
- Shevchenko KV, V'iunova TV, Nagaev IIu, Andreeva LA, Alfeeva LIu, Miasoedov NF. [Proteolysis of semax analogues with different N-terminal amino acids by aminopeptidases]. Bioorg Khim. 2011 Jul-Aug;37(4):475-82. Russian. https://pubmed.ncbi.nlm.nih.gov/22096989/
- Dolotov OV, Zolotarev IuA, Dorokhova EM, Andreeva LA, Alfeeva LIu, Grivennikov IA, Miasoedov NF. Sviazyvanie analoga ACTH-(4-10)-geptapeptida Semaks s plazmaticheskimi membranami bazal'nykh iader perednego mozga krysy i ego biodegradatsiia [The binding of Semax, ACTH 4-10 heptapeptide, to plasma membranes of the rat forebrain basal nuclei and its biodegradation]. Bioorg Khim. 2004 May-Jun;30(3):241-6. Russian. https://pubmed.ncbi.nlm.nih.gov/15344653/
- Zolotarev IuA, Dadaian AK, Dolotov OV, Kozik VS, Kost NV, Sokolov OIu, Dorokhova EM, Meshavkin VK, Inozemtseva LS, Gabaeva MV, Andreeva LA, Alfeeva LIu, Pavlov TS, Badmaeva KE, Badmaeva SE, Bakaeva ZV, Kopylova GN, Samonina GE, Vas'kovskiĭ BV, Grivennikov IA, Zozulia AA, Miasoedov NF. [Evenly tritium-labeled peptides and their in vivo and in vitro biodegradation]. Bioorg Khim. 2006 Mar-Apr;32(2):183-91. Russian. PMID: 16637290. https://pubmed.ncbi.nlm.nih.gov/16637290/
